PhaseBio Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Jonathan Mow
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 9.2yrs |
| CEO ownership | n/a |
| Management average tenure | 3.6yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M
Aug 12PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?
Aug 10
PhaseBio shares surge after inking exclusive license agreement for bentracimab
Jun 17What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?
Mar 04If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%
Jan 08PhaseBio Pharmaceuticals EPS misses by $0.15
Nov 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -US$103m |
| Mar 31 2022 | n/a | n/a | -US$115m |
| Dec 31 2021 | US$2m | US$562k | -US$131m |
| Sep 30 2021 | n/a | n/a | -US$118m |
| Jun 30 2021 | n/a | n/a | -US$112m |
| Mar 31 2021 | n/a | n/a | -US$111m |
| Dec 31 2020 | US$2m | US$529k | -US$99m |
| Sep 30 2020 | n/a | n/a | -US$80m |
| Jun 30 2020 | n/a | n/a | -US$66m |
| Mar 31 2020 | n/a | n/a | -US$47m |
| Dec 31 2019 | US$1m | US$436k | -US$39m |
| Sep 30 2019 | n/a | n/a | -US$33m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$27m |
| Dec 31 2018 | US$596k | US$359k | -US$24m |
| Sep 30 2018 | n/a | n/a | -US$22m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$12m |
| Dec 31 2017 | US$436k | US$338k | -US$10m |
Compensation vs Market: Insufficient data to establish whether Jonathan's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Insufficient data to compare Jonathan's compensation with company performance.
CEO
Jonathan Mow (58 yo)
9.2yrs
Tenure
US$1,529,108
Compensation
Mr. Jonathan P. Mow, MBA, serves as Chief Executive Officer of Veralox Therapeutics Inc. since June 2023 and serves as its Director. He has been Chief Executive Officer of PhaseBio Pharmaceuticals, Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.2yrs | US$1.53m | no data | |
| Chief Restructuring Officer & Principal Financial Officer | 1.5yrs | no data | no data | |
| Senior Vice President of Technical Operations | 2.6yrs | no data | no data | |
| SVP, General Counsel & Corporate Secretary | 4.6yrs | no data | no data | |
| Senior Vice President of Human Resources | 4.6yrs | no data | no data | |
| Chief Commercial Officer | 2.5yrs | no data | no data |
3.6yrs
Average Tenure
52.5yo
Average Age
Experienced Management: PHAS.Q's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.7yrs | US$1.53m | no data | |
| Independent Director | 5.3yrs | US$82.86k | no data | |
| Independent Director | 5.4yrs | US$76.36k | 0.020% $ 0.01 | |
| Independent Chairman of the Board | 22.3yrs | US$116.36k | 0.074% $ 0.04 | |
| Independent Director | 2.7yrs | US$62.58k | 0.0051% $ 0.002 | |
| Independent Director | 6.2yrs | US$87.36k | 0.083% $ 0.04 | |
| Independent Director | 4.3yrs | US$77.86k | 0.0075% $ 0.004 |
5.4yrs
Average Tenure
57yo
Average Age
Experienced Board: PHAS.Q's board of directors are considered experienced (5.4 years average tenure).